Company intelligence / Profile preview
Regeneris Medical
- Ownership
- Private
- Employees
- ~11
- Development stage
- Commercial
Overview
Regeneris Medical has conducted open-label studies using autologous stem cell therapies—primarily SVF from adipose tissue and PRP—for musculoskeletal conditions and other chronic diseases. Results are described as promising but remain investigational; no published pivotal trial results or FDA approvals reported.
- Therapeutic areas
- NeurologyImmunologyDermatologyRheumatology
- Modalities
- Stem cell therapy (specifically adult mesenchymal stem cells)Platelet Rich Plasma (PRP) therapyStromal Vascular Fraction (SVF) therapyCell therapyBiologic (as a general category for autologous cell-based therapies)
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Regeneris Medical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Regeneris Medical.